Pulmonology Pulmonology
Pulmonol 2018;24:170-3 - Vol. 24 Num.3 DOI: 10.1016/j.rppnen.2017.10.001
Case series
Macitentan in daily clinical practice: A single centre, 1-year experience
S. Cadenas-Menéndeza,, , P. Álvarez-Vegaa, J. Martín-Moreirasb, M. Barreiro-Pérezb, M.Á. Gómez-Sánchezc, P.L. Sánchez-Fernándezb
a Pulmonology Service, Pulmonary Hypertension Unit, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
b Cardiology Service, Pulmonary Hypertension Unit, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
c Cardiology Service, Hospital General Nuestra Señora del Prado, CIBER de Enfermedades Respiratorias (CIBERES), Talavera de la Reina, Spain
Received 14 July 2017, Accepted 02 October 2017
Abstract

The effectiveness and safety of macitentan, a dual endothelin-receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH), were shown in an extensive clinical trial oriented towards morbidity and mortality events. Our aim was to describe a single centre's experience of the utilization of macitentan in patients with PAH in clinical practice settings. Thirteen patients with different aetiologies and previous PAH treatments were studied. After 12 months of macitentan treatment, 11 patients improved their functional class (FC), all patients improved their 6-minute walk distance (6MWD) test, and 10 patients lowered their NT-proBNP plasma levels. Additionally, cardiac imaging parameters were also improved. No cases resulted in hospitalization, septostomy, transplant or death.

Keywords
Pulmonary arterial hypertension, Macitentan, Endothelin-receptor antagonist, Clinical practice, Phosphodiesterase 5 inhibitors, Prostaglandins
Pulmonol 2018;24:170-3 - Vol. 24 Num.3 DOI: 10.1016/j.rppnen.2017.10.001
Cookies Policy
x
To improve our services and products, we use cookies (own or third parties authorized) to show advertising related to client preferences through the analyses of navigation customer behavior. Continuing navigation will be considered as acceptance of this use. You can change the settings or obtain more information by clicking here.